RxDoctor Payments Data

Chante Carroll

Acute Care · Baltimore, MDNPI 1730899840

Payments from drug & device makers

$443in general payments, 2019–2025

Across 21 payments — averaging $21.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Collegium Pharmaceutical, Inc.$159
  • Vertex$49
  • Electronic Waveform Lab, Inc.$49
  • Mallinckrodt Hospital Products Inc.$46
  • Boston Scientific$39
  • Protega Pharmaceutials Inc$33
  • plus $66 from 3 others

What the payments were for

  • Food & beverage$443100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Collegium Pharmaceutical, Inc.9$159
Vertex2$49
Electronic Waveform Lab, Inc.2$49
Mallinckrodt Hospital Products Inc.2$46
Boston Scientific1$39
Protega Pharmaceutials Inc2$33
AbbVie1$29
Pfizer1$19
Biotronik NRO, Inc.1$18

How this compares

$443 in reported general payments places this provider in the 60th percentile of 502 acute care providers in Maryland.

See all acute care providers in Maryland

Medicare billing

Part B allowed, 2024
$214,265
Medicare patients
285
Services billed
1,789

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate65$38,021
OxycontinOxycodone Hcl57$34,171
Oxycodone Hcl693$13,161
NucyntaTapentadol Hcl16$12,582
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen287$7,368
MovantikNaloxegol Oxalate16$6,511
Morphine Sulfate ErMorphine Sulfate216$5,741
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen247$4,561
Hydromorphone ErHydromorphone Hcl15$4,390
Diclofenac Sodium71$3,645
Tramadol Hcl ErTramadol Hcl61$3,453
Naloxone Hcl39$2,977
Lidocaine29$2,665
Gabapentin255$2,146
Tramadol Hcl228$1,987

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta$159$50,60381 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 502 acute care providers in Maryland.

Other acute care in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →